Strata Critical Medical, Inc.
5.05+0.12 (+2.43%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · SRTA · USD
Key Stats
Market Cap
429.91MP/E (TTM)
-Basic EPS (TTM)
-0.24Dividend Yield
0%Recent Filings
8-K
Strata acquires Keystone Perfusion
Strata Critical Medical completed its $124 million acquisition of Keystone Perfusion Services on September 16, 2025, blending 88% cash with 12% stock to snag a leader in organ recovery and normothermic perfusion. This move forges an end-to-end organ transplant platform, tapping Keystone's projected $65 million 2025 revenue and $13 million adjusted EBITDA while eyeing 50%+ growth. Up to $23 million in earn-outs hinge on hitting profit targets through 2028. Integration risks loom if synergies falter.
8-K
Passenger sale closes, rebrands to Strata
Strata Critical Medical completed the sale of its Passenger business to Joby Aero on August 29, 2025, netting $76 million in Joby stock after adjustments, with up to $45 million more possible via earnouts and holdback releases. This sharpens focus on medical transport, triggering a name change from Blade Air Mobility and co-CEO leadership under Melissa Tomkiel and William Heyburn. Yet restrictions bind: eight-year non-compete on short-distance flights. 2025 revenue guidance holds at $160-170 million.
10-Q
Q2 FY2025 results
Blade Air Mobility posted Q2 revenue of $70.8M, up 4.2% y/y, fueled by 17.6% growth in the Medical segment to $45.1M from new contracts, though Passenger dipped 13.2% y/y to $25.7M after exiting Canada. Gross margin expanded to 18.2% from 16.7%, with operating loss narrowing to $5.0M from $12.1M y/y, thanks to lower G&A and marketing costs. Cash climbed to $58.8M, bolstered by $49.1M in investing inflows from maturing securities, while free cash flow turned positive at $45.8M (derived). Post-quarter, Blade agreed to sell its Passenger business to Joby Aviation for up to $125M in cash or stock, pending closing conditions. Yet regulatory hurdles in aviation persist.
8-K
Blade sells Passenger to Joby
Blade Air Mobility announced Q2 2025 results with revenue up 4.2% to $70.8 million, driven by 17.6% medical segment growth to $45.1 million, while net loss narrowed to $3.7 million and Adjusted EBITDA rose to $3.2 million. The company agreed to sell its Passenger division to Joby Aviation for up to $125 million, leaving the Medical division as a standalone public entity rebranded Strata Critical Medical. This divestiture sharpens focus on stable medical logistics. Deal closes soon.
8-K
Blade sells Passenger to Joby
Blade Air Mobility agreed to sell its Passenger business to Joby Aviation for up to $125 million in cash or stock, including $90 million at closing and $35 million in earnouts tied to retention and performance over 12-18 months post-close. This divestiture sharpens Blade's focus on its medical logistics arm, rebranding as Strata, while imposing eight-year non-compete restrictions on short-distance services. CEO Rob Wiesenthal transitions to Joby, with co-CEOs Melissa Tomkiel and Will Heyburn stepping in at Strata. Deal closes by December 1, 2025, or risks termination.
IPO
Employees
Sector
Industry
FLYYQ
Spirit Aviation Holdings, Inc.
0.37+0.01
FTAI
FTAI Aviation Ltd.
174.00-5.39
HRBR
Harbor Diversified, Inc.
0.98-0.01
JETR
Star Jets International, Inc.
0.00+0.00
JOBY
Joby Aviation, Inc.
17.03+1.42
SKAS
Saker Aviation Services Inc.
6.80+0.00
SOAR
Volato Group, Inc.
1.71-0.13
SRFM
Surf Air Mobility Inc.
3.96-0.08
SSKN
Strata Skin Sciences, Inc.
1.74-0.19
UP
Wheels Up Experience Inc.
1.46-0.02